Eplerenone Pharmacia

Danny Yearn-Hian Liew; Jennifer Martin; Henry Krum

Eplerenone Pharmacia

Danny Yearn-Hian Liew
, Jennifer Martin
, Henry Krum

Research output: Contribution to journal › Review Article › Research › peer-review

Abstract

Pharmacia Corp (formerly GD Searle & Co) is developing eplerenone, an aldosterone receptor antagonist, as a potential treatment for congestive heart failure and systemic hypertension. The compound has been registered for hypertension and Pharmacia plans to submit a supplemental NDA for congestive heart failure in the first half of 2003 based on positive results from a phase III clinical trial.

Original language	English
Pages (from-to)	316-322
Number of pages	7
Journal	Current Opinion in Investigational Drugs
Volume	4
Issue number	3
Publication status	Published - 1 Mar 2003

Cite this

@article{c59998a5f9e444cd9feb127a0d2b3bae,

title = "Eplerenone Pharmacia",

abstract = "Pharmacia Corp (formerly GD Searle \& Co) is developing eplerenone, an aldosterone receptor antagonist, as a potential treatment for congestive heart failure and systemic hypertension. The compound has been registered for hypertension and Pharmacia plans to submit a supplemental NDA for congestive heart failure in the first half of 2003 based on positive results from a phase III clinical trial.",

author = "Liew, \{Danny Yearn-Hian\} and Jennifer Martin and Henry Krum",

year = "2003",

month = mar,

day = "1",

language = "English",

volume = "4",

pages = "316--322",

journal = "Current Opinion in Investigational Drugs",

issn = "1472-4472",

publisher = "Thomson Reuters",

number = "3",

}

TY - JOUR

T1 - Eplerenone Pharmacia

AU - Liew, Danny Yearn-Hian

AU - Martin, Jennifer

AU - Krum, Henry

PY - 2003/3/1

Y1 - 2003/3/1

N2 - Pharmacia Corp (formerly GD Searle & Co) is developing eplerenone, an aldosterone receptor antagonist, as a potential treatment for congestive heart failure and systemic hypertension. The compound has been registered for hypertension and Pharmacia plans to submit a supplemental NDA for congestive heart failure in the first half of 2003 based on positive results from a phase III clinical trial.

AB - Pharmacia Corp (formerly GD Searle & Co) is developing eplerenone, an aldosterone receptor antagonist, as a potential treatment for congestive heart failure and systemic hypertension. The compound has been registered for hypertension and Pharmacia plans to submit a supplemental NDA for congestive heart failure in the first half of 2003 based on positive results from a phase III clinical trial.

UR - https://www.scopus.com/pages/publications/0038300037

M3 - Review Article

C2 - 12744223

SN - 1472-4472

VL - 4

SP - 316

EP - 322

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

IS - 3

ER -

Eplerenone Pharmacia

Abstract

Other files and links

Cite this